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were on active lipid lowering treatment (LLT) at admission. Mean
atorvastatin dose was 22 mg per day and 2.7% received ezetimibe
in combination with a statin. At discharge from hospital, 3767
patients received LLT expressed as a mean atorvastatin dose of
36 mg per day with 4.8% receiving ezetimibe on top of a statin.
After 120 days, intensity in lipid lowering treatment was reduced
to 32 mg per day with 4.9% of the patients receiving ezetimibe and
a statin. Of note, during this 4-month follow up period, only 32% of
all patients received laboratory lipid testing. 37% attained the low
density lipoprotein cholesterol (LDL-C) target value of o70 mg/dl
after 120 days. There are differences in the therapy administered as
well as in the switch strategies when comparing the data from the
respective countries studied.
Conclusions: Only one in three patients achieved the LDL-C target
value following only marginal improvements in atorvastatin dose
or combination therapy after an ACS event.
& 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Biology
ore specific
subject areaDyslipidemia and cardiovascular riskype of data Tables and Figures
ow data was
acquiredWorldwide surveyata format Analyzed
xperimental
factorsObservational, longitudinal registryxperimental
featuresComparison of lipid lowering therapies administered in patients post acute
coronary syndrome, as well as LDL-C target achievement.ata source
locationInstitut für Herzinfarktforschung, Ludwigshafen, Germanyata accessibility Data are included in this articleValue of the data
 These data have been collected under real life conditions across the world.
 Stratification per country can help to facilitate a scientific dialogue for the benefit of coronary
patients in these countries, but also help to compare treatment standards between geographies of
the world.
 The data presented can help to guide treatment decisions for novel lipid lowering agents.1. Data
See Figs 1 and 2 and Tables 1–3.
Fig. 1. LDL-C target attainment for ACS cohort. (A) LDL-C target attainment by pre-ACS risk level (ESC/EAS guidelines);
(B) Proportion of ACS patients with an LDL-C level of o70 mg/dL at hospital admission and at 120-day follow-up (for patients
with values available at both time points, N ¼ 1071).
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Fig. 2. LDL-C target value attainment by region. Target value attainment rates were calculated for the 1,071 patients with LDL-C
data at both time points.
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DYSIS II ACS was a multicenter, longitudinal, observational study that included 3867 patients from
18 countries in Europe, the Middle East, South-, Southeast- and East-Asia.
The study was approved by the relevant ethics committees and carried out in agreement with local
laws.
Inclusion criteria were as follows: 1) provision of written informed consent, 2) aged Z18, 3)
hospitalized for an ACS in 2013–2014, 4) availability of a full fasting or non fasting lipid profile based
on blood drawn within 24 hours of admission, and 5) not participating in a clinical trial. Data were
assessed at presentation for an acute coronary syndrome (ACS), at hospital stay and discharge, as well
as after a predefined period of 120 days.
The ESC/EAS dyslipidemia guidelines (2011) were used as a reference in order to determine target
value attainment after 120 days [1]. Low density lipoprotein (LDL-C) treatment target thus was
o70 mg/dl. Since the guidelines also highlight the use of statins in highest tolerated dose, followed
by the use of lipid lowering combination therapy, we determined statin dose administered, calculated
as atorvastatin equivalent doses [2].
Data were collected in an electronic case report form and processed in a central web-based
database at the Institut für Herzinfarktforschung, Ludwigshafen, Germany. It was used for both col-
lection and storage of the data.
Table 1
Indicates the change in lipid-lowering therapy at admission to a hospital for the treatment of an ACS, as well as the changes applied during hospital stay, at discharge and after a 120 day follow up period.
At admission During hospital stay At discharge 120 days post ACS
N LLT (%) AED E/S LLT (%) AED E/S % LLT AED E/S N % LLT AED E/S Lipid lab during
follow up (%)
LDL-Co70 mg/dl
at follow up (%)
Egypt 199 147 (26.1) 29.72 0 (0.0) 199 (100.0) 54.02 0 (0.0) 199 (100) 53.12 0 (0.0) 151 148 (98.0) 45.74 0 (0.0) 23.8% 5.6%
France 468 277 (40.8) 21.72 20 (4.3) 450 (96.2) 48.02 14 (3.0) 453 (96.8) 48.86 14 (3.0) 326 312 (95.7) 40.81 15 (4.6) 48.5% 50.6%
Germany 461 270 (41.4) 18.42 14 (3.0) 447 (97.0) 20.59 19 (4.1) 447 (97.0) 20.91 23 (5.0) 390 357 (91.5) 21.83 21 (5.4) 27.9% 19.3%
Greece 200 159 (20.5) 20.31 12 (6.0) 196 (98.0) 31.28 9 (4.5) 196 (98.0) 31.18 12 (6.0) 194 188 (96.9) 29.87 15 (7.7) 44.3% 22.1%
Hong Kong 140 67 (52.1) 13.86 1 (0.7) 135 (96.4) 16.46 1 (0.7) 131 (93.6) 17.36 1 (0.7) 136 132 (97.1) 17.18 0 (0.0) 56.6% 48.1%
India 521 404 (22.5) 28.51 2 (0.4) 519 (99.6) 45.54 1 (0.2) 510 (97.9) 43.4 0 (0.0) 513 482 (94.0) 37.01 0 (0.0) 15.6% 57.5%
Ireland 57 32 (43.9) 32.67 1 (1.8) 55 (96.5) 66.98 0 (0.0) 57 (100) 62.46 1 (1.8) 56 56 (100.0) 60 1 (1.8) 57.1% 46.9%
Italy 212 142 (33) 26.71 9 (4.2) 207 (97.6) 57.84 3 (1.4) 206 (97.2) 56.04 9 (4.2) 171 168 (98.2) 50.55 11 (6.4) 31.6% 37.0%
Jordan 40 24 (40) 24.35 1 (2.5) 39 (97.5) 35.26 5 (12.5) 40 (100) 35.13 7 (17.5) 30 30 (100) 37.33 0 (0.0) 3.3% 100.0%
Lebanon 82 61 (25.6) 24.49 1 (1.2) 82 (100) 55.98 1 (1.2) 82 (100) 45.18 2 (2.4) 78 76 (97.4) 38.42 1 (1.3) 28.2% 27.3%
Philippines 48 26 (45.8) 48.27 0 (0.0) 46 (95.8) 60.22 0 (0.0) 47 (97.9) 56.74 0 (0.0) 21 21 (100) 44.5 0 (0.0) 19.0% 50.0%
Saudi Arabia 150 140 (6.7) 23.79 18 (12.0) 150 (100) 59.8 26 (17.3) 150 (100) 38.13 64 (42.7) 150 150 (100) 40.27 55 (36.7) 15.3% 8.7%
Singapore 126 84 (33.3) 19.37 2 (1.6) 121 (96) 35.37 4 (3.2) 122 (96.8) 35.29 4 (3.2) 108 106 (98.1) 33.89 3 (2.8) 61.1% 34.8%
South Korea 308 162 (47.4) 16.91 11 (3.6) 300 (97.4) 22.57 34 (11.0) 306 (99.4) 22.47 36 (11.7) 301 296 (98.3) 20.72 27 (9.0) 26.2% 62.0%
Taiwan 130 58 (55.4) 14.42 4 (3.1) 114 (87.7) 18.58 2 (1.5) 113 (86.9) 17.69 3 (2.3) 123 97 (78.9) 18.47 3 (2.4) 33.3% 36.6%
Thailand 320 188 (41.3) 16.9 6 (1.9) 317 (99.1) 27.92 6 (1.9) 311 (97.2) 28.07 7 (2.2) 285 275 (96.5) 28.2 11 (3.9) 51.9% 25.7%
UAE 200 129 (35.5) 23.51 1 (0.5) 199 (99.5) 40.43 5 (2.5) 197 (98.5) 40.1 4 (2.0) 166 161 (97.0) 39.28 1 (0.6) 17.5% 44.8%
Vietnam 205 151 (26.3) 17.4 1 (0.5) 204 (99.5) 21.84 0 (0.0) 200 (97.6) 19.93 0 (0.0) 191 186 (97.4) 18.49 1 (0.5) 13.6% 26.9%
All 3867 2521 (34.8) 22.36 104 (2.7) 3780 (97.8) 37.43 130 (3.4) 3767 (97.4) 35.88 187 (4.8) 3390 3241 (95.6) 32.41 165 (4.9) 31.6% 37.0%
LLT, Lipid lowering treatment; AED, Atorvastatin equivalent dose; E/S, ezetimibe in combination with any statin: ACS, acute coronary syndrome; LDL-C, low density lipoprotein cholesterol; UAE, United

















Regional differences in lipid-lowering therapy.
Admission (N ¼ 3867) Follow-up (N ¼ 3558)
Asia Europe Middle
East
P value Asia Europe Middle
East
P value
Statin monotherapy 58.8% 53.8% 69.5% o0.001 89.8% 83.1% 85.4% o0.001
Non-statin monotherapy 1.0% 2.4% 0.6% o0.001 0.4% 0.7% 0.2% N.S.
Statinþezetimibe 1.5% 4.0% 3.1% o0.001 2.7% 5.5% 9.9% o0.001
Statinþother non-statin 2.1% 2.8% 1.5% N.S. 2.2% 5.8% 2.8% o0.001
Not treated 36.6% 37.1% 25.3% o0.001 4.4% 4.9% 1.7% o0.001
Atorvastatin dose equivalent, mean7SD
mg/daya
22718 22717 25714 o0.001 27718 35725 41718 o0.001
SD, standard deviation; N.S., not significant.
a In statin treated patients (N ¼ 2466 at admission; N ¼ 3226 at follow up 120 days after the ACS).
Table 2
Predictors of LDL-C target value attainment among treated ACS patients.
Full model Stepwise model
OR 95% CI P value OR 95% CI P value
Age Z70 1.20 0.96–1.50 0.109 – – –
Female 0.60 0.47–0.77 o0.001 0.61 0.48–0.78 o0.001
BMI 430 kg/m2 0.63 0.49–0.81 o0.001 0.61 0.48–0.78 o0.001
Current smoking 0.59 0.44–0.77 o0.001 0.57 0.43–0.74 o0.001
Sedentary lifestyle 0.90 0.73–1.10 0.293 – – –
Stable angina 0.88 0.65–1.20 0.418 – – –
Chronic kidney disease 1.52 1.09–2.13 0.014 1.58 1.14–2.20 0.006
Type 2 diabetes mellitus 1.33 1.08–1.64 0.007 1.31 1.07–1.61 0.009
History of chronic heart failure 1.38 0.99–1.94 0.060 1.40 1.00–1.96 0.050
Hypertension 0.98 0.77–1.25 0.881 – – –
Statin dose (atorvastatin dose equivalent, mg/day) 1.01 1.004–1.016 o0.001 1.009 1.004–1.015 0.001
BMI, body mass index; CI, confidence interval; OR, odds ratio.
A.K. Gitt et al. / Data in Brief 16 (2018) 369–375374SAS version 9.3 (Cary, NC, USA) was used for performing the calculations. Data are presented as
absolute numbers and percentages (n/N), pertaining to either the baseline sample or the 3,390
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